Damla Gunenc

8PUBLICATIONS
49CO-AUTHORS
Predictive and prognostic markersMolecular targetsMedical infection agents (incl. prions)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|May 27, 2026
Prognostic and Treatment-Specific Predictive Implications of HER2 Expression in RAS Wild-Type Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Study.

|Mar 28, 2026
Tyrosine Kinase Inhibitor Therapy in Metastatic Medullary Thyroid Carcinoma: Real-World Data from Turkish Oncology Group.

Sedat Yıldız, Hacer Demir, Talha Özüdoğru

|Feb 25, 2026
DUSP29 does not regulate melanoma-myoblast interactions in a skeletal muscle co-culture model.

Sercan Ön, Harika Atmaca İlhan, Damla Günenç

|Dec 30, 2025
Claudin-4 Overexpression Predicts Poor Survival and Platinum Resistance in Epithelial Ovarian Cancer: A Potential Biomarker for Clinical Decision-Making.

Özlem Kutlu, Damla Günenç, Duygu Ayaz

|Jul 30, 2025
RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches.

Osman Sütcüoğlu, Hasan Çağrı Yıldırım, Elvina Almuradova

|Mar 27, 2025
A Narrative Review of RAS Mutations in Early-Stage Colorectal Cancer: Mechanisms and Clinical Implications.

Hasan Cagri Yildirim, Damla Gunenc, Elvina Almuradova

Pageof 2

Frequent Collaborators

2 joint publications

Şaziye Burçak Karaca Yayla

2 joint publications

Hasan Çağrı Yıldırım

2 joint publications

Osman Sutcuoglu

2 joint publications

Halil Taşkaynatan